March 1, 2024

The latest report by IMARC Group, titled Preeclampsia Diagnostics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028, offers a comprehensive analysis of the industry, which comprises insights on the global preeclampsia diagnostics market report. The global market size reached US$ 0.90 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 1.1 Billion by 2028, exhibiting a growth rate (CAGR) of 3.4% during 2023-2028.

Preeclampsia diagnostics refers to the suite of medical procedures and tests used to identify and diagnose preeclampsia, a potentially serious pregnancy complication characterized by high blood pressure and damage to organs, typically the liver and kidneys. Preeclampsia can pose significant risks to both the mother and the developing fetus, making early and accurate diagnosis crucial for appropriate medical management. The diagnostic process often involves monitoring blood pressure, assessing protein levels in the urine, and conducting various blood tests to detect abnormal changes in organ function and platelet count. These diagnostics are fundamental in distinguishing preeclampsia from other pregnancy-related conditions and ensuring timely intervention when necessary.

For an in-depth analysis, you can refer sample copy of the report:

Preeclampsia Diagnostics Market Trends and Drivers:

The market is witnessing substantial growth, driven by the increasing awareness and emphasis on maternal and fetal health that have significantly boosted the demand for preeclampsia diagnostics. As more women seek comprehensive prenatal care, the need for accurate and timely detection of preeclampsia has grown, resulting in a burgeoning market for related diagnostic tests and technologies. Besides, advancements in medical technology have played a pivotal role in expanding the market. Innovations in diagnostic tools and techniques, such as the development of automated blood pressure monitoring devices and improved biochemical assays for proteinuria, have enhanced the accuracy and efficiency of preeclampsia diagnosis. These technological advancements provide healthcare professionals with more reliable results and streamline the diagnostic process, reducing the time required for assessment. Another significant driver of the market is the increasing prevalence of risk factors associated with preeclampsia. Factors such as obesity, diabetes, and hypertension are on the rise globally, leading to a higher predisposition to preeclampsia among pregnant women. Consequently, healthcare providers are more inclined to recommend regular preeclampsia screening for at-risk individuals, further stimulating market growth. Furthermore, government initiatives aimed at improving maternal healthcare have spurred the adoption of preeclampsia diagnostics. Public health programs and policies that promote prenatal care and early detection of pregnancy complications have increased accessibility to these diagnostics, particularly in developing regions where maternal mortality rates are higher.

Report Segmentation:

The report has segmented the market into the following categories:

Test Type Insights:

  • Blood Tests
  • Urine Analysis

Product Insights:

  • Instruments
  • Consumables

End-User Insights:

  • Hospitals
  • Specialty Clinics
  • Diagnostic Centers
  • Others

Regional Insights:

  • North America (U.S. & Canada)
  • Europe (Germany, United Kingdom, France, Italy, Spain, Russia, and Others)
  • Asia Pacific (China, India, Japan, South Korea, Indonesia, Australia, and Others)
  • Latin America (Brazil, Mexico)
  • Middle East & Africa

Competitors Landscape with Key Players:

  • Diabetomics Inc.
  • DRG Instruments GmbH
  • F. Hoffmann-La Roche Ltd.
  • Metabolomic Diagnostics Limited
  • MOMM Diagnostics
  • PerkinElmer Inc.
  • Sera Prognostics
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.

Note: If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us


134 N 4th St. Brooklyn, NY 11249, USA

USA: +1-631-791-1145 | Asia: +91-120-433-0800

Email:[email protected]

Follow us on Twitter: @imarcglobal